ST百灵(002424.SZ)：一种治疗糖尿病或其并发症的中药制剂获得专利申请受理通知书

Core Viewpoint - ST Bailin (002424.SZ) has received a patent application acceptance notice from the National Intellectual Property Administration for a traditional Chinese medicine formulation aimed at treating diabetes and its complications, which will enhance the company's core intellectual property protection [1] Group 1: Patent Application Details - The accepted patent application is for a "traditional Chinese medicine formulation for treating diabetes or its complications," based on years of research from the company's Tang Ning Tong Luo project [1] - The confidentiality protection scope includes formula composition, production processes, and multiple treatment areas, with a confidentiality period aligned with the "secret" confidentiality period under the National Confidentiality Law of the People's Republic of China [1] Group 2: Implications for the Company - The acceptance of this confidential patent will provide comprehensive and tighter core intellectual property protection for the Tang Ning Tong Luo project [1] - If the patent is ultimately granted, it will help the company avoid core technology leakage and accelerate clinical promotion and market transformation, thereby enhancing the company's core competitiveness [1]